Preclinical study of new TB drugs and drug combinations in mouse models

Recent Patents on Anti-Infective Drug Discovery

Volumn 3, Issue 2, 2008, Pages 102-116

  Nikonenko, Boris V ^a,b   Sacksteder, Katherine A ^a   Hundert, Sam ^a   Einck, Leo ^a   Nacy, Carol A ^a  

^a SEQUELLA INC   (United States)

^b Central TB Research Institute   (Russian Federation)

Author keywords

Drugs; Mouse model; Tuberculosis

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 1,5 BIS(4 CHLOROPHENYL) 2 METHYL 3 (4 METHYL 1 PIPERAZINYLMETHYL)PYRROLE; 1,5 DIARYL 2 METHYL 3 (4 METHYLPIPERAZIN 1 YL)METHYLPYRROLE; 2 ETHYL 5 NITRO 2,3 DIHYDRO(2,1B)IMIDAZOOXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; ANTIMYCOBACTERIAL AGENT; CAPURAMYCIN; CGI 17341; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; LL 3858; MOXIFLOXACIN; N GERANYL N' (2 ADAMANTYL)ETHANE 1,2 DIAMINE; NITROIMIDAZOLE DERIVATIVE; OPC 67683; PYRAZINAMIDE; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; R 207920; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; RS 112997; RS 118641; RS 124922; SQ 109; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; COLONY FORMING UNIT; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPERIMENTAL MOUSE; HUMAN; LOW DRUG DOSE; LUNG TUBERCULOSIS; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATENT; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TUBERCULOSIS; ANIMAL; ANTIBIOTIC RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG COMBINATION; MOUSE; STRUCTURE ACTIVITY RELATION; TIME;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; MICE; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TUBERCULOSIS;

EID: 52449101550     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489108784746579     Document Type: Review

References (110)

1. Flynn JL, Cooper A, Bishai W. Animal models of tuberculosis. In: Tuberculosis and the Tubercle bacilluss. ASM Press, Washington, DC. 2005; 547-560.
2. Gupta UD, Katoch VM. Animal models of tuberculosis. Tuberculosis (Edinb) 2005; 85: 277-293.
3. Allen SS, McMurray DN. Coordinate cytokine gene expression in vivo following induction of tuberculous pleurisy in guinea pigs. Infect Immun 2003; 71:4271-4277.
4. Kradolfer F. Models of tuberculosis in mice and guinea pigs. In: experimental models in antimicrobial chemotherapy. Edit by O Zak and MA Sande. V2 Academic Press (London) 1986; 321-345.
5. Nikonenko BV, Hanrahan C. Murine model of tuberculosis. in vitro and in vivo study. Rus J Immunol 2002; 7:307-322.
6. Hunter PA. Tuberculosis models of animals other than mice and guinea pigs. Models of tuberculosis in mice and guinea pigs. In experimental models in antimicrobial chemotherapy. Edit by O Zak and MA Sande. V2 Academic Press (London) 1986; 347-378.
7. Dannenberg A M Jr. Rabbit model of tuberculosis. In: Tuberculosis: Pathogenesis, protection and control. Edit by BR Bloom. ASM. Washington, DC. 1994; 149-156.
8. Flynn JL, Capuano S V, Croix D, et al. Non-human primates: a model for tuberculosis research. Tuberculosis (Edinb) 2003; 83: 116-118.
9. Capuano S V III, Croix DA, Pawar S, et al. Experimental Mycobacterium tuberculosis Infection of Cynomolgus Macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect Immun 2003; 71: 5831-5844.
10. Elwood RL, Wilson S, Blanco JC, et al. The American cotton rat: a novel model for pulmonary tuberculosis. Tuberculosis (Edinb) 2007; 87:145-154.
11. Jain SK, Hernandez-Abanto SM, Cheng QJ, et al. Accelerated detection of Mycobacterium tuberculosis genes essential for bacterial survival in guinea pigs, compared with mice. J Inf Dis 2007, 195: 1634-642.
12. Lenaerts AJ, Gruppo V, Brooks JV, Orme IM. Rapid in vivo screening of experimental drugs fro tuberculosis using γ interferon gene-disrupted mice. Antimicrob Agents Chemother 2003; 47: 783-785.
13. Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother 2005; 49: 2294-2301.
14. Nikonenko BV, Samala R, Einck L, Nacy CA. Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 4550-4555.
15. Bogatcheva E, Hanrahan C, Nikonenko B, et al. Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis. J Med Chem 2006; 49: 3045-3048.
16. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivate with promising action against tuberculosis in vitro in mice. Plos Medicine 2006; 3: 2131-2143.
17. Grosset J, Truffot-Pernot C, Lacroix C, Ji B. Antagonism between isoniazid and the combination pirazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992; 36: 548-551.
18. Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999, 43:1189-1191.
19. Lenaerts AM, Chase SE, Chmielewski AJ, Cynamon MH. Evaluation of Rifapentine in long-term treatment regimen for tuberculosis in mice. Antimicrob Agents Chemother 1999; 43: 2356-2360.
20. Daniel N, Lounis N, Ji B, et al. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Am J Respir Crit Care Med 2000; 161: 1572-1577.
21. Shoen CM, Chase SE, DeStefano MS, Harpster TS, Chmielewski AJ, Cynamon MH. Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice. Antimicrob Agents Chemother 2000; 44:1458-1462.
22. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo Activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 1022-1025.
23. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob. Agents Chemother 2002; 46: 1875-1879.
24. Andries K, Verhasselt P, Guilliemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-227.
25. Jia L, Tomaszewski JE, Hanrahan C, et al. Pharmacodynamics and pharmacokinetics of SQ109 a new diamine-based antitubercular drug. Brit J Pharmacol 2005; 144: 80-87.
26. Protopopova M, Hanrahan C, Nikonenko B, et al. Indemnification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamins. J Antimicrob Chemother 2005; 56: 968-974.
27. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 2006; 50: 3543-3547.
28. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007; 51:1563-1565.
29. Cynamon MH, Sklaney M. Gatifloxacin and ethionamide as foundation for therapy of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2442-2444.
30. Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2809-2812.
31. Brooks JV, Orme IM. Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins n the mouse aerosol infection model. Antimicrob Agents Chemother 1998; 42: 3047-3048.
32. Orme I, Secrist J, Anathan S, et al. Guest commentary. Search for new drugs for treatment of tuberculosis. Antimicrob Agents Chemother 2001; 45: 1943-1946.
33. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-parmacodinamics of rifampin in aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118-2124.
34. Jayaram R, Shandil RK, Gaonkar S, et al. Isoniazid pharmacokinetics-parmacodinamics in aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48: 2951-2957.
35. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversation in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-426.
36. Nuermberger E, Tyagi S, Williams K, Rosenthal I, Bishai W, Grosset JH. Rifapentine, moxifloxacin or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med 2005; 172: 1452-1456.
37. Nuermberger E, Rosenthal I, Tyagi S, et al. Combination chemotherapy with nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2006; 50: 2621-2625.
38. Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005; 49: 2289-2293.
39. Grosset J, Ji B. Experimental chemotherapy of mycobacterial diseases. In PRJ Gangadharam and P.A. Jenkins (ed.), Mycobacteria. Chemotherapy. Chapman & Hall, New York, NY 1998; (2): 51-97.
40. Radaeva TV, Nikonenko BV, Mischenko VV, Averbakh MMJr, Apt AS. Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice. Tuberculosis 2005; 85: 65-72.
41. Bass JB, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149: 1359-1374.
42. Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against Murine tuberculosis. Antimicrob Agents Chemother 2007; 51: 1011-1015.
43. Nikonenko BV, Protopopova MN, Samala R, Einck L, Nacy C. Combination chemotherapy of M. tuberculosis-infected mice with SQ109 and first line TB drugs. Abstract. 45th ICAAC. Washington, DC 2005; 1475.
44. Chen P, Gearhart J, Protopopova M, Einck L, Nacy CA. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J Antimicrob Chemother 2006; 58: 332-337.
45. Dong Y, Zhao X, Kreiswirth BN, Drlica K. Mutant prevention concentration as measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000; 44: 2581-2584.
46. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007; 44: 681-688.
47. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001; 33 (Suppl. 3): S147-S156.
48. Almeida D, Nuermberger E, Tyagi S, Bishai WR, Grosset J. in vivo Validation of the mutant selection window hypothesis with moxifloxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 2007; 51: 4261-4266.
49. Lecoeur HF, Lagrange PH, Truffot-Pernot C, Gheorghiu M, Grosset J. Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Clin Exp Immunol 1989; 76: 458-462.
50. Kramnik I, Dietrich WF, Demant P, Bloom BR. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000; 97:8560-5605.
51. Lewin CS, Howard BM, Smith JT. 4-Quinolone interactions with gyrase subunit B inhibitors. J Med Microbiol 1991; 35: 358-362.
52. Willmott CJ, Critchlow SE, Eperon IC, Maxwell A. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase. J Mol Biol 1994; 242: 351-363.
53. Gonzáles I, Georgiou M, Alcaide F, Balas D, Liñares J, de la Campa AG. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group Streptococci. Antimicrob Agents Chemother 1998; 42: 2792-2798.
54. Schedletzky H, Wiedemann B, Heisig P. The effect of moxifloxacin on its topoisomerases from Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother 1999; 43 (Suppl. B): 31-37.
55. Blondeau JM. A review of the comparative invitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999; 43 Suppl B: 1-11.
56. Martínez-Martínez L, Pascual, A, Suárez, AI, Perea EJ. In-vitro Activity of levofloxacin, ofloxacin and D-ofloxacin against Coryneform bacteria and Listeria monocytogenes. J Antimicrob Chemother 1999; 43 (Suppl. 3): 27-32.
57. Stratchounski LS, Kretchikov VA. Moxifloxacin - the new fluoroquinolone with broad spectrum activity. Clin Microb Antimicrob Chemother 2001; 3: 243-259.
58. Collins CH, Uttley AM. invitro Susceptibility of mycobacteria to ciprofloxacin. J Antimicrob Chemother 1985; 16: 575-580.
59. Tomioka H, Sato K, Saito H. Comparative in vitro and in vivo activity of fleroxacin and ofloxacin against various mycobacteria. Tubercle 1991; 72: 176-180.
60. Saito H, Tomioka H, Sato K, Dekio S. in vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob Agents Chemother 1994; 38: 2877-2882.
61. Jacobs MR. Fluoroquinolones as chemotherapeutics against mycobacterial Infections. Cur Pharmaceutical Des 2004; 10: 3213-3220.
62. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculosis agents with special reference to their in vitro and in vivo antimicrobial activities. Curr Pharm Des 2006; 12: 4047-4070.
63. Casal M, Ruiz P, Herreras A, et al. Study of the in vivo susceptibility of M. tuberculosis to ofloxacin in Spain. Int J Tuberc Lung Dis 2000; 4: 588-591.
64. Hoffner SE, Gezelius L, Olsson-Liljequist B. In vitro Activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997; 40:885-888.
65. Protopopova M, Bogatcheva E, Nikonenko B, Hundert S, Einck L, Nacy CA. In search of new cures for tuberculosis. Med Chem 2007; 3: 301-316.
66. Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:653-657.
67. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. in vitro and in vivo Activities of moxifloxacin and clinofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 2066-2069.
68. Rosenthal IM, Williams K, Tyagi S, et al. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med 2005; 172:1457-1462.
69. Rosenthal IM, Williams K, Tyagi S, et al. Potent weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 2006; 174: 94-101.
70. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a state of stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004; 170: 1131-1134.
71. Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of Rifapentine dures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4(12): e344 (doi:10.1371/journal.pmed.0040344).
72. Gosling RD, Uiso LO, Sam NE, et al. The bacterial activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 168:1342-1345.
73. Gosling R, Gillespie S. Moxifloxacin treatment of tuberculosis. Antimicrob Agents Chemother 2004; 48: 3642.
74. Pletz MWR, De Roux A, Roth A, Neumann K-H, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004; 48: 780-782.
75. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tubercul Lung Dis 2006; 10: 605-612.
76. Kaiser GlobalHealthReporting.org, Tuberculosis. Antibiotic Moxifloxacin Could Shorten TB Treatment Regimens, Study Says [Sep 19, 2007].
77. Ashtekar DR, Costa-Perira R, Nagrajan K, Vishvanathan N, Bhatt AD, Rittel W. in vitro and in vivo Activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1993; 37: 183-186.
78. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-966.
79. Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit C of Mycobacterial ATP synthase. Nat Chem Biol 2007; 3: 323-324.
80. Andries, K.J.L.M., Van Gestel, J.F.E.: US20070249667 (2007).
81. Lenaerts AJ, Hoff D, Aly S, et al. Location of persisting mycobacteria in the guinea pig model of tuberculosis revealed by R207910. Antimicrob Agents Chemother 2007; 51: 3338-33345.
82. Lee R, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE. 3d. Combinatorial lead optimization of [1, 2] -diamines based on EMB as potential anti-tuberculosis preclinical candidates. J Comb Chem 2003; 5: 172-187.
83. Jia L, Tomaszewski JE, Noker P, Gorman GS, Glaze E, Protopopova M. Simultaneous estimation of pharmacokinetic properties of three anti-tubercular ethambutol analogs resulting from combinatorial lead optimization. J Pharm Biomed Anal 2005; 37: 793-799.
84. Jia L, Tomaszewski JE, Hanrahan C, et al. Pharmacodynamic and pharmacokinetic characteristics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005; 144: 80-87.
85. Yamaguchi H, Sato S, Yoshida S, Takada K, Utoh M, Seto H. Capuramycin, a new nucleoside antibiotic. Taxonomy, fermentation, isolation and characterization. J Antibiot 1986; 39: 1047-1053.
86. Hotoda H, Daigo M, Furukawa M, et al. Synthesis and antibacterial activity of capuramycin analogs. Part 2: acylated derivates of capuramycin-related compounds. Bioorg Med Chem Lett 2003; 13: 2833-2836.
87. Kimura K-I, Bugg TDH. Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis. Nat Prod Rep 2003; 20: 252-273.
88. Koga T, Fukuoka T, Doi N, et al. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare in vivo and in vitro. J Antimicrob Chemother 2004; 54: 755-760.
89. Doi N. Development of the intratracheal infection model of experimental murine mycobacteriosis: comparison with the intravenous infection model. Kekkaku 1998; 73: 339-347.
90. Deidda D, Lampis G, Fioravanti R, et al. Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains. Antimicrob Agents Chemother 1998; 42: 3035-3037.
91. Arora SK, Sinha N, Sinha RK, Uppadhayaya RS, Modak VM, Tilekar A. Synrhesis and in vitro anti-mycobacterial activity of a novel anti-TB composition LL 4858. 44th ICAAC, Washington, DC. 2004 Abstract F-1115; 212.
92. Sinha RK, Arora SK, Sinha N, Modak VM. In vivo Activity of LL4858 against Mycobacterium tuberculosis. Abstract 44th ICAAC, Washington, DC 2004 Abstract F-1116. p.212.
93. Sasaki H, Haraguchi Y, Itotani M, et al. Synthesis and antituberculosis activity of a novel series of optically active 6-Nitro-2, 3-dihydroimidazo[2,1-b] oxazoles. J Med Chem 2006; 49: 7854-7860.
94. Tomishige T, Matsumoto M. Intracellular activity of OPC-67683 against M. tuberculosis H37Rv in THP-1 human macrophages and A549 type II alveolar cells. Abstract. 45th ICAAC. Washington, DC 2005; F1465.
95. Boechat, N., Costa, M.D.S., Lourenco, M.C.D.S., Neves, J.I., Genestra, M.D.S., Ferreira, V. F.: WO07019660 (2007).
96. Dietze R, Teixeria L, Rocha LM, et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2001; 45: 1972-1976.
97. Lounis N, Roscigno G. in vitro and in vivo Activities of new rifamycin derivatives against mycobacterial infections. Curr Pharm Des 2004; 10: 3229-3238.
98. Hirata T, Saito H, Tomioka H, et al. in vitro and in vivo Activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2295-2303.
99. Arioli V, Berti M, Carniti G, Randisi E, Rossi E, Scotti R. Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative. J Antibiot Tokyo 1981; 34: 1026-1032.
100. Klemens SP, Cynamon MH. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1996; 40: 298-301.
101. Reddy MV, Luna-Herrera J, Daneluzzi D, Gangadharam PR. Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Tuberc Lung Dis 1996; 77:154-159.
102. Lenaerts AM, Chase SE, Cynamon MH. Evaluation of rifalazil in combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model. Antimicrob Agents Chemother 2000; 44: 3167-3168.
103. Ji B, Truffot-Pernot C, Lacroix C, et al. Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148: 1541-1546.
104. Lenaerts AM, Chase SE, Chmielewski AJ, Cynamon MH. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. Antimicrob Agents Chemother 1999; 43: 2356-2360.
105. Schwander S, Rüsch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tubercl Lung Dis 1995; 76: 210-218.
106. Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/ isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006; 173:922-926.
107. Gordin FM. Rifapentine for the treatment of tuberculosis. Is it all It can be? Am J Respir Crit Care Med 2004; 169: 1176-1177.
108. Singh, J., Nathan, C.F., Bryk, R., Samy, R., Pupek, K., Gurney, M.: WO08005651 (2008).
109. Ascher, G.D., Berner, H., Mang, R.: EP1875903 (2008).
110. Coler, R., Lobet, Y., Reed, S.: EP1877426 (2008).